TY - JOUR
T1 - Perspectives in Immunotherapy
T2 - meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
AU - Ascierto, Paolo A.
AU - Avallone, Antonio
AU - Bifulco, Carlo
AU - Bracarda, Sergio
AU - Brody, Joshua D.
AU - Emens, Leisha A.
AU - Ferris, Robert L.
AU - Formenti, Silvia C.
AU - Hamid, Omid
AU - Johnson, Douglas B.
AU - Kirchhoff, Tomas
AU - Klebanoff, Christopher A.
AU - Lesinski, Gregory B.
AU - Monette, Anne
AU - Neyns, Bart
AU - Odunsi, Kunle
AU - Paulos, Chrystal M.
AU - Powell, Daniel J.
AU - Rezvani, Katayoun
AU - Segal, Brahm H.
AU - Singh, Nathan
AU - Sullivan, Ryan J.
AU - Fox, Bernard A.
AU - Puzanov, Igor
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th–December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer.
AB - The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th–December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer.
KW - Biomarkers
KW - Checkpoint inhibitors
KW - Combination therapy
KW - Immunotherapy
KW - Tumor microenvironment
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85165318992&partnerID=8YFLogxK
U2 - 10.1186/s12967-023-04329-7
DO - 10.1186/s12967-023-04329-7
M3 - Article
C2 - 37475035
AN - SCOPUS:85165318992
SN - 1479-5876
VL - 21
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 488
ER -